Ng, Hwee-Ing http://orcid.org/0000-0001-6519-1942
Tuong, Zewen K. http://orcid.org/0000-0002-6735-6808
Fernando, Germain J. P. http://orcid.org/0000-0003-3260-0548
Depelsenaire, Alexandra C. I.
Meliga, Stefano C.
Frazer, Ian H. http://orcid.org/0000-0002-8002-4680
Kendall, Mark A. F.
Funding for this research was provided by:
Department of Health | National Health and Medical Research Council (APP1059012)
Article History
Received: 12 May 2019
Accepted: 11 September 2019
First Online: 11 October 2019
Competing interests
: M.A.F.K. declares a financial interest as the founder of Vaxxas Pty Ltd and is the inventor on several patents currently licensed by Vaxxas Pty Ltd. While a significant component of this research was being conducted, in addition to his Professorial role at The University of Queensland, M.A.F.K. served as a Vaxxas Director, Chief Technology Officer and Chair of the Vaxxas Advisory Board. H.-I.N., A.C.I.D. and G.J.P.F. were all in the Kendall laboratory for most of this research—funded by the ARC and UQ sources. H.-I.N. and A.C.I.D. are now employed by Vaxxas Pty Ltd. G.J.P.F. is an inventor on some Nanopatch™ patents and is now a consultant for Vaxxas Pty Ltd. Vaxxas Pty Ltd is a commercial company developing the Nanopatch™ for vaccine delivery in humans. All other authors delcare no competing interests.